David Winter Named President & Chief Executive Officer of Human Organ Sciences, Inc.; New Wholly Owned Research Subsidiary of SangStat.MENLO PARK, Calif.--(BW HealthWire)--June 8, 1998--SangStat, The Transplant Company(R) (Nasdaq: SANG), announced today that David L. Winter, M.D., has been named President and Chief Executive Officer of Human Organ Sciences(TM), Inc., a wholly-owned subsidiary of SangStat dedicated to transplantation tissue engineering research. The company is in early phase research to develop Mini-Organs(TM), functional human organ tissues grown in vitro in vitro /in vi·tro/ (in ve´tro) [L.] within a glass; observable in a test tube; in an artificial environment. in vi·tro adj. In an artificial environment outside a living organism. , as an alternative to experimental animal organs (xenotransplantation xen·o·trans·plan·ta·tion n. The surgical transfer of cells, tissues, or especially whole organs from one species to another. xenotransplantation ) for addressing the limited supply of solid organs from human donors for transplantation. Dr. Winter was previously President and Chief Operating Officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. at SangStat Medical Corporation where he now assumes the role of Chairman of SangStat's Scientific, Medical & Ethical Affairs board. Prior to joining SangStat in 1995, Dr. Winter had held several senior management positions including President and Chief Operating Officer at GenPharm International, Inc. in California, Vice President, clinical research and development, and Vice President, scientific and external affairs for Sandoz Pharmaceuticals Corporation (now Novartis) and NASA NASA: see National Aeronautics and Space Administration. NASA in full National Aeronautics and Space Administration Independent U.S. Director of Life Sciences. "David has been of great value to SangStat in helping us prepare the important research, development, and operational foundations for our near-term anticipated commercial activities," said Philippe Pouletty, MD, Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . "We believe that future growth in transplantation requires a significant expansion in the treatment options for end organ end organ n. The encapsulated termination of a sensory nerve. end organ, n the expanded termination of a nerve fiber in muscle, skin, mucous membrane, or other structure. failure as the supply of human donor organs is severely limited and the use of animal organs for xenotransplantation is still fraught with many uncertainties." Dr. Pouletty added, "As CEO of our newly formed subsidiary, Human Organ Sciences, Inc., David will be responsible for fostering transplantation tissue research from the lab to the bedside through academic and corporate collaborations. The goal is to research novel technologies while maintaining a tight control on SangStat's research expenditures." "The development of Mini-Organs is an exciting and novel approach to potentially providing an alternative solution to the shortage of organs for the thousands of people on the transplant waiting lists," said Dr. Winter. "Our initial focus will be in vitro development of functional liver tissue." Dr. Winter received his M.D. from Washington University School of Medicine Washington University School of Medicine, located in St. Louis, Missouri, is one of the most competitive and highly regarded medical schools and biomedical research institutes in the United States. . Dr. Winter belongs to many professional associations, including the American Society of Transplant Physicians, the International Transplantation Society, and the Space Medicine branch of the Aerospace Medical Association. Dr. Winter is succeeded by Jean-Jacques Bienaime, previously Senior Vice President, Corporate Marketing and Business Development at Rhone Poulenc Rorer, Inc., who joins SangStat today in the position of President and Chief Operating Officer. SangStat is a specialty pharmaceutical company applying a disease management approach to improve the outcome of organ transplantation. The Company has a total of 12 monitoring and therapeutic products and product candidates to address the pre-transplant, acute care and chronic phases of transplantation. SangStat is located in Menlo Park, California Menlo Park is a city in San Mateo County, California in the United States of America. It is located at latitude 37°29' North, longitude 122°9' East. Menlo Park had 30,785 inhabitants as of the 2000 U.S. Census. , and operates The Transplant Pharmacy(r), a comprehensive pharmacotherapy pharmacotherapy /phar·ma·co·ther·a·py/ (-ther´ah-pe) treatment of disease with medicines. phar·ma·co·ther·a·py n. Treatment of disease through the use of drugs. management program, and wholly-owned subsidiaries, SangStat Atlantique S.A., SangStat's European base of operations Noun 1. base of operations - installation from which a military force initiates operations; "the attack wiped out our forward bases" base air base, air station - a base for military aircraft army base - a large base of operations for an army in Nantes, France, SangStat Canada, Ltd., in Mississauga, Ontario, Canada and Human Organ Sciences, Inc. in Menlo Park, California.
CONTACT: SangStat
Maree Wall
V.P. Corporate Communications
650/688-2331
or
BMC Communications
Brad Miles, 212/477-9007 x17
|
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion